Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Company expects to lock database in June and
remains on track to report key outcomes later in July.

Pepinemab targets astrocyte reactivity and neuroinflammation,
believed to be key drivers of neurodegeneration.